ReproNovo
PrivateLast Round
Series A
May 21, 2025
Total Funding Raised
$65M
Company Overview
ReproNovo operates in Healthcare & Life Sciences and is based in Lausanne. Its latest recorded funding round was a Series A round in May 2025.
ReproNovo is a biopharmaceutical company that develops innovative treatments for reproductive medicine and women's health.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReproNovo Comparables
Compare ReproNovo with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vivalyx | 84% | |
| Bridge to Life | 84% | |
| Granata Bio | 83% |
For institutional investors. Book with your work email.
ReproNovo Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ReproNovo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ALSA Ventures | Series A |
| M Ventures | Series A, Seed |
| Ysios Capital | Series A |
| AXA IM Alts | Series A |
| BNP Paribas Asset Management | Series A |
| Jeito Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors grew 291% MoM, reaching 1.6K.
- May 21, 2025
$65M Series A round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 5, 2026
Fierce Biotech named Repronovo one of 2026’s Fierce 15 biotechnology companies, recognizing it among the industry’s most innovative and promising private biotechnology companies, on Oct 5th '26, in Switzerland and Denmark.
For institutional investors. Book with your work email.
ReproNovo Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ReproNovo's valuation, stock price, and market status.
Is ReproNovo a public or private company?
ReproNovo is a private company.
What is the current stock price of ReproNovo?
ReproNovo is a private company, so its shares have no public market price. Caplight tracks ReproNovo's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ReproNovo worth (valuation)?
Valuation information for ReproNovo is not publicly available.
Can I buy ReproNovo stock?
ReproNovo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ReproNovo's last funding round?
ReproNovo's most recent funding round was Series A on May 21, 2025.
Who are the main investors in ReproNovo?
Key investors in ReproNovo include M Ventures, Jeito Capital.
Will ReproNovo IPO soon?
No public IPO plans have been announced for ReproNovo.
How can I track ReproNovo secondary market activity?
Caplight tracks bids, offers, and trades in ReproNovo's shares on secondary markets.